QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virusGlobeNewsWire • 10/04/23
QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completenessGlobeNewsWire • 09/28/23
QIAGEN's QuantiFERON solutions recommended for use by kidney specialists in TunisiaGlobeNewsWire • 09/28/23
QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability ReportGlobeNewsWire • 09/27/23
QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kitsGlobeNewsWire • 09/25/23
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlookGlobeNewsWire • 08/08/23
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines' AYVAKIT® (avapritinib) in gastrointestinal stromal tumorsGlobeNewsWire • 08/07/23
QIAGEN expands range of digital PCR kits and services for the biopharma industryGlobeNewsWire • 07/18/23
FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)GlobeNewsWire • 06/20/23
QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notesGlobeNewsWire • 06/16/23